Mineralys Therapeutics Files Form 4
Ticker: MLYS · Form: 4 · Filed: Apr 16, 2026
Sentiment: neutral
Topics: insider-filing, ownership-change
TL;DR
Mineralys Therapeutics filed a Form 4 on 4/15/26 for 4/13/26 transactions.
AI Summary
On April 15, 2026, Mineralys Therapeutics, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occurred on April 13, 2026. The filing was accepted by the SEC on April 15, 2026.
Why It Matters
Form 4 filings indicate changes in stock ownership by company insiders, which can signal their confidence or lack thereof in the company's future performance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of ownership changes and does not inherently indicate new risks for the company.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Issuer
- 0001933414 (company) — Issuer CIK
- 2026-04-15 (date) — Filing Date
- 2026-04-13 (date) — Period of Report
- Jon Congleton (person) — Reporting Person
- 0001644975 (person) — Reporting Person CIK
FAQ
What type of SEC filing is this?
This is a Form 4 filing, a Statement of changes in beneficial ownership of securities.
When was the filing accepted by the SEC?
The filing was accepted on April 15, 2026.
What is the period of report for this filing?
The period of report is April 13, 2026.
What is the CIK for Mineralys Therapeutics, Inc.?
The CIK for Mineralys Therapeutics, Inc. is 0001933414.
Who is listed as a reporting person in this filing?
Jon Congleton is listed as a reporting person.
Filing Details
This Statement of Changes in Beneficial Ownership (Form 4) was filed with the SEC on April 16, 2026 by Jon Congleton regarding Mineralys Therapeutics, Inc. (MLYS). Form 4 filings disclose purchases, sales, or other changes in ownership by company insiders such as officers, directors, and major shareholders.